Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA clears belzutifan-pembrolizumab combination to delay kidney cancer's return

FDA clears belzutifan-pembrolizumab combination to delay kidney cancer's return

New Capabilities

A two-drug regimen becomes a new post-surgery option for high-risk clear cell kidney cancer

June 12th, 2026: FDA approves the belzutifan-pembrolizumab combination

Overview

Updated Jun 12

Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.

The approval rests on a 1,841-patient trial. Adding belzutifan to pembrolizumab cut the risk of the cancer returning or death by 28% compared with pembrolizumab alone. The benefit came with more side effects, so doctors now weigh longer disease control against higher toxicity.

Why it matters

For high-risk kidney cancer patients, surgery often isn't the end. This regimen lowers the odds the cancer comes back.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1,841
Patients in the trial
All had clear cell kidney cancer removed by surgery and a high risk of recurrence.
28%
Lower risk of recurrence or death
Reduction with the combination versus pembrolizumab alone.
0.72
Hazard ratio for disease-free survival
Below 1.0 means the combination delayed recurrence; the result was statistically significant.
52.1%
Serious side-effect rate
Grade 3 or worse treatment-related events on the combination, versus 30.2% on pembrolizumab alone.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Toni Choueiri
Toni Choueiri
Genitourinary oncologist, Dana-Farber Cancer Institute
Leading investigator in adjuvant kidney cancer trials

Organizations Involved

Merck & Co.
Merck & Co.
Pharmaceutical company
Maker of both belzutifan (Welireg) and pembrolizumab (Keytruda)

Merck developed both drugs in the newly approved combination and ran the trial behind it.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted the approval

The FDA reviews and approves new drugs and new uses for existing drugs in the United States.

Timeline

August 2021 June 2026

4 events Latest: June 12th, 2026 · 3 months ago
Tap a bar to jump to that date

  1. FDA approves the belzutifan-pembrolizumab combination

    Latest Approval

    Drawing on the 1,841-patient LITESPARK-022 trial first reported at the 2026 ASCO genitourinary cancers meeting, the FDA clears the combination to delay recurrence after surgery.

  2. Belzutifan approved for advanced kidney cancer

    Approval

    The FDA expands belzutifan to patients with advanced clear cell kidney cancer whose disease progressed after earlier treatment.

  3. Pembrolizumab becomes a post-surgery standard

    Approval

    Based on the KEYNOTE-564 trial, the FDA approves pembrolizumab alone after kidney removal for high-risk patients. It later showed patients lived longer.

  4. Belzutifan wins its first approval

    Approval

    The FDA clears belzutifan for tumors tied to von Hippel-Lindau disease. It is the first drug to block the HIF-2-alpha protein, a target long thought undruggable.

Scenarios

1

Treatment guidelines add the combination as a recommended option

Likely Resolves by End of 2026

Discussed by: Urology Times and OncLive commentary calling the data a new standard-of-care candidate

Cancer treatment guidelines steer what oncologists prescribe. With a significant disease-free survival benefit in hand, the National Comprehensive Cancer Network (NCCN) could list the belzutifan-pembrolizumab combination as a recommended post-surgery option for high-risk clear cell kidney cancer. That listing usually follows quickly after an FDA approval of this strength.

2

Longer follow-up shows the combination helps patients live longer

Uncertain Resolves by Q2 2028

Discussed by: Trial investigators and Merck, who note overall survival data is still maturing

The approval rests on delaying recurrence, not yet on longer life. Overall survival, the clearest measure of benefit, remains immature in LITESPARK-022. Adjuvant pembrolizumab took years to show a survival edge in its own trial. If the combination follows suit, the case for routine use strengthens; if not, uptake may stall given the added side effects.

3

European regulators approve the same combination

Possible Resolves by End of 2027

Discussed by: Industry analysts tracking Merck's global filing strategy for belzutifan

A U.S. approval often signals a European filing. The European Medicines Agency (EMA) reviews the same kind of evidence on its own timeline. If it follows the FDA, the combination would reach high-risk kidney cancer patients across the European Union, widening the regimen's use well beyond the United States.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2017

Adjuvant sunitinib approval (2017)

The FDA approved sunitinib after surgery for high-risk kidney cancer based on the S-TRAC trial. The drug delayed recurrence but never showed patients lived longer. Side effects were heavy.

Then

Many oncologists hesitated to prescribe it. Adoption stayed low despite the approval.

Now

It became a cautionary case that a delay in recurrence does not always translate into longer life or wide use.

Why this matters now

It shows why the pending survival data for belzutifan-pembrolizumab matters so much. A recurrence benefit alone may not be enough to win over doctors.

November 2021

Adjuvant pembrolizumab approval (2021)

The FDA approved pembrolizumab alone after surgery for high-risk kidney cancer, based on the KEYNOTE-564 trial. Years later, follow-up showed patients on the drug lived longer than those on placebo.

Then

It became the first post-surgery treatment to gain traction in kidney cancer in years.

Now

It set the survival benchmark and the backbone that newer combinations, including this one, are built on.

Why this matters now

The new combination adds belzutifan to this exact drug. Its value depends on beating pembrolizumab alone, the standard it builds on.

August 2021

Belzutifan drugs an 'undruggable' target (2021)

The FDA approved belzutifan for tumors tied to von Hippel-Lindau disease. It was the first drug to block HIF-2-alpha, a protein that drives clear cell kidney cancer and was long considered impossible to target with a pill.

Then

It gave patients with a rare inherited cancer syndrome a non-surgical option.

Now

It opened a new line of attack on kidney cancer that Merck has since tested across multiple settings.

Why this matters now

This combination pushes that mechanism into earlier, more common disease, pairing it with immunotherapy right after surgery.

Sources

(6)
OncLive Oncology Nursing News Urology Times Merck U.S. Food and Drug Administration The ASCO Post